Activity of Brigatinib in Alectinib-Resistant ALK-Positive NSCLC According to ALK Plasma Mutation Status From J-ALTA Trial

被引：0
|
作者：
Hida, T. [1 ]
Katayama, R. [2 ]
Nishio, M. [3 ]
Yoshida, T. [4 ]
Kumagai, T. [5 ]
Toyozawa, R. [6 ]
Shimokawaji, T. [7 ]
Goto, K. [8 ]
Nakagawa, K. [9 ]
Seto, T. [10 ]
Yamamoto, N. [11 ]
Asato, T. [12 ]
Hiraoka, K. [13 ]
Zhang, P. [14 ]
Ohe, Y. [15 ]
机构：
[1] Aichi Canc Ctr, Dept Thorac Oncol, Nagoya, Aichi, Japan
[2] Japanese Fdn Canc Res, Div Expt Chemotherapy, Ctr Canc Chemotherapy, Tokyo, Japan
[3] Japanese Fdn Canc Res, Dept Thorac Med Oncol, Canc Inst Hosp, Tokyo, Japan
[4] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan
[5] Osaka Int Canc Inst, Dept Thorac Oncol, Osaka, Japan
[6] Natl Hosp Org Kyushu Canc Ctr, Fukuoka, Japan
[7] Kanagawa Canc Ctr, Yokohama, Kanagawa, Japan
[8] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan
[9] Kindai Univ, Fac Med, Dept Med Oncol, Higashiosaka, Osaka, Japan
[10] NHO Kyushu Canc Ctr, Thorac Oncol, Fukuoka, Japan
[11] Wakayama Med Univ, Wakayama, Japan
[12] Takeda Pharmaceut Co Ltd, Oncol Therapeut Area Unit Japan & Asia, Tokyo, Japan
[13] Takeda Pharmaceut Co Ltd, Japan Oncol Business Unit, Tokyo, Japan
[14] Millennium Pharmaceut Inc, Cambridge, MA USA
[15] Natl Canc Ctr, Tokyo, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
brigatinib; alectinib-resistant; ALK-positive NSCLC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P75.01
引用
收藏
页码：S572 / S572
页数：1
相关论文
共 50 条
  • [21] Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
    Sugawara, Shunichi
    Kondo, Masashi
    Yokoyama, Toshihide
    Kumagai, Toru
    Nishio, Makoto
    Goto, Koichi
    Nakagawa, Kazuhiko
    Seto, Takashi
    Yamamoto, Nobuyuki
    Kudou, Kentarou
    Asato, Takayuki
    Zhang, Pingkuan
    Ohe, Yuichiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1828 - 1838
  • [22] Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?
    Ou, Sai-Hong Ignatius
    Kim, Edward S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
  • [23] Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
    Shunichi Sugawara
    Masashi Kondo
    Toshihide Yokoyama
    Toru Kumagai
    Makoto Nishio
    Koichi Goto
    Kazuhiko Nakagawa
    Takashi Seto
    Nobuyuki Yamamoto
    Kentarou Kudou
    Takayuki Asato
    Pingkuan Zhang
    Yuichiro Ohe
    International Journal of Clinical Oncology, 2022, 27 : 1828 - 1838
  • [24] Quality-adjusted survival with brigatinib (BRG) versus crizotinib (CRZ) in ALK-positive (ALK plus ) non-small cell lung cancer (NSCLC): Results from the ALTA-1L trial
    Campelo, M. R. Garcia
    Wan, Y.
    Lin, M.
    Chen, T.
    Shen, J.
    Zhang, P.
    Humphries, M. J.
    Camidge, D. R.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1077 - S1078
  • [25] Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
    Shunichi Sugawara
    Masashi Kondo
    Toshihide Yokoyama
    Toru Kumagai
    Makoto Nishio
    Koichi Goto
    Kazuhiko Nakagawa
    Takashi Seto
    Nobuyuki Yamamoto
    Kentarou Kudou
    Takayuki Asato
    Pingkuan Zhang
    Yuichiro Ohe
    International Journal of Clinical Oncology, 2022, 27 : 1839 - 1840
  • [26] Correction to: Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
    Shunichi Sugawara
    Masashi Kondo
    Toshihide Yokoyama
    Toru Kumagai
    Makoto Nishio
    Koichi Goto
    Kazuhiko Nakagawa
    Takashi Seto
    Nobuyuki Yamamoto
    Kentarou Kudou
    Takayuki Asato
    Pingkuan Zhang
    Yuichiro Ohe
    International Journal of Clinical Oncology, 2023, 28 : 724 - 725
  • [27] Brigatinib vs Crizotinib in patients (pts) with ALK inhibitornaive advanced ALK plus NSCLC from the phase 3 ALTA-1L trial
    Griesinger, F.
    Camidge, D. R.
    Kim, H. R.
    Ahn, M. -J.
    Yang, J. C. -H.
    Han, J. -Y.
    Lee, J. -S.
    Hochmair, M.
    Li, J. Y. -C.
    Chang, G. -C.
    Lee, K. H.
    Gridelli, C.
    Delmonte, A.
    Campelo, Garcia M. R.
    Kim, D. -W.
    Bearz, A.
    Morabito, A.
    Felip, E.
    Califano, R.
    Ghosh, S.
    Spira, A.
    Gettinger, S.
    Tiseo, M.
    Haney, J.
    Kerstein, D.
    Popat, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 75 - 76
  • [28] Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
    Garcia, Christine
    Abrahami, Devin
    Polli, Anna
    Chu, Haitao
    Chandler, Conor
    Tan, Min
    Kelton, John Mark
    Thomaidou, Despina
    Bauer, Todd
    CLINICAL LUNG CANCER, 2024, 25 (07) : 634 - 642
  • [29] Activity of brigatinib based on genomic alterations detected on ctDNA at baseline and at progression in ALK inhibitor-naive advanced ALK plus NSCLC from the ALTA-1L trial
    Mezquita, L.
    Laguna Montes, J. C.
    Ferriol-Galmes, M.
    Albarran Artahona, V. M.
    Garcia Pardo de Santayana, M.
    Gorria Puga, T.
    Crous Brunol, C.
    Jimenez, M.
    Bernabeu Aracil, M. B.
    Navarro Mendivil, A. F.
    Reguart Aransay, N.
    Arcocha, A.
    Teixido, C.
    Dingemans, A-M. C.
    Auclin, E.
    ANNALS OF ONCOLOGY, 2024, 35 : S818 - S818
  • [30] ALTA-2: Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib
    Kim, Edward S.
    Barlesi, Fabrice
    Mok, Tony
    Ahn, Myung-Ju
    Shen, Junwu
    Zhang, Pingkuan
    Ou, Sai-Hong Ignatius
    FUTURE ONCOLOGY, 2021, 17 (14) : 1709 - 1719
12345